Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director | January 02, 2018 | January 03, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date January 02, 2018 · Filed January 03, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $380.95 · Expires 2028-01-02 | Direct | 7,439 |
Reported balance
After 2018-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-01-02 · Grant · Acquired 7,439 · Balance 7,439 F1: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2018 Filed Jan 3, 2018 21:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 7,439 | $0.00 Strike: $380.95 | $0.00 |
DisclosureSEC source: 0001237899-18-000005 · edgardoc.xml · derivative · entry 1 BAKER CHARLES A · CIK 0001225470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,439 Underlying: Common Stock · 7,439 shares Expires 2028-01-02 F1 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| September 29, 2017 Filed Oct 3, 2017 20:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $18.61 | $0.00 |
DisclosureSEC source: 0001237899-17-000023 · edgardoc.xml · derivative · entry 3 BAKER CHARLES A · CIK 0001225470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires 2019-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| September 29, 2017 Filed Oct 3, 2017 20:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,000 | $450.00 | $900,000.00 |
DisclosureSEC source: 0001237899-17-000023 · edgardoc.xml · nonDerivative · entry 2 BAKER CHARLES A · CIK 0001225470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 29, 2017 Filed Oct 3, 2017 20:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 2,000 | $18.61 | $37,220.00 |
DisclosureSEC source: 0001237899-17-000023 · edgardoc.xml · nonDerivative · entry 1 BAKER CHARLES A · CIK 0001225470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 7,830 | $0.00 Strike: $376.69 | $0.00 |
DisclosureSEC source: 0001237899-17-000010 · edgardoc.xml · derivative · entry 1 BAKER CHARLES A · CIK 0001225470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,830 Underlying: Common Stock · 7,830 shares Expires 2027-01-03 F1 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 12, 2016 Filed Dec 14, 2016 22:41 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $18.61 | $0.00 |
DisclosureSEC source: 0001237899-16-000085 · edgardoc.xml · derivative · entry 7 BAKER CHARLES A · CIK 0001225470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 3,000 shares Expires 2019-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 12, 2016 Filed Dec 14, 2016 22:41 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $394.33 | $78,866.00 |
DisclosureSEC source: 0001237899-16-000085 · edgardoc.xml · nonDerivative · entry 6 BAKER CHARLES A · CIK 0001225470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on December 12, 2016 at prices ranging from $394.24 to $ 394.41. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 12, 2016 at each separate price. Read SEC document |
| December 12, 2016 Filed Dec 14, 2016 22:41 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 600 | $393.64 | $236,184.00 |
DisclosureSEC source: 0001237899-16-000085 · edgardoc.xml · nonDerivative · entry 5 BAKER CHARLES A · CIK 0001225470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,200 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 600 shares of Company stock on December 12, 2016 at prices ranging from $393.39 to $393.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 12, 2016 at each separate price. Read SEC document |
| December 12, 2016 Filed Dec 14, 2016 22:41 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 400 | $392.41 | $156,964.00 |
DisclosureSEC source: 0001237899-16-000085 · edgardoc.xml · nonDerivative · entry 4 BAKER CHARLES A · CIK 0001225470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,800 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 400 shares of Company stock on December 12, 2016 at prices ranging from $392.00 to $392.82. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 12, 2016 at each separate price. Read SEC document |
| December 12, 2016 Filed Dec 14, 2016 22:41 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,200 | $391.36 | $469,632.00 |
DisclosureSEC source: 0001237899-16-000085 · edgardoc.xml · nonDerivative · entry 3 BAKER CHARLES A · CIK 0001225470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,200 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 1,200 shares of Company stock on December 12, 2016 at prices ranging from $391.02 to $391.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 12, 2016 at each separate price. Read SEC document |
| December 12, 2016 Filed Dec 14, 2016 22:41 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 600 | $390.67 | $234,402.00 |
DisclosureSEC source: 0001237899-16-000085 · edgardoc.xml · nonDerivative · entry 2 BAKER CHARLES A · CIK 0001225470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,400 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 600 shares of Company stock on December 12, 2016 at prices ranging from $390.26 to $390.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 12, 2016 at each separate price. Read SEC document |
| December 12, 2016 Filed Dec 14, 2016 22:41 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 3,000 | $18.61 | $55,830.00 |
DisclosureSEC source: 0001237899-16-000085 · edgardoc.xml · nonDerivative · entry 1 BAKER CHARLES A · CIK 0001225470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.